​Cancer Immunotherapy – Emerging Targets to Unleash the Immune Response Against Cancer 

Welcome Message

Thank you for expressing an interest in this Cancer Immunotherapy Workshop which will be held on 12 and 13 October.

Over the past two decades, basic and translational cancer immunology research has been translated into remarkable clinical benefits for our patients. Cancer immunotherapy is now integrated with or follows other treatment modalities such as surgery, radiotherapy and chemotherapy, or it is used as a standalone first line treatment. The optimal treatment options including combinations and modalities are under continuous exploration; this helps control toxicities and other undesired effects of immune interventions.

Molecular and immune profiling of cancers along with a deep understanding of the tumor microenvironment will guide improvements in targeted interventions to control cancer. The impact of radiotherapy and chemotherapy on the tumor biology and the microenvironment and immune responses to cancer are subject to intense research. This will be further discussed during this workshop. The biomarkers for successful immune interventions in cancer are emerging and cancer antigens and cancer vaccines will be revisited.

Qatar has substantially invested in building a state-of-the-art cancer research infrastructure and environment.  Cancer immunology research is a major focus and a great area of collaboration; joint efforts with international centers of excellence in the field have been established and will continue to evolve.

This workshop will nurture discussion and the exchange of ideas to support and encourage clinicians and researchers in every stage stages of their professional development.

Poster sessions and oral abstract presentations as selected by the Scientific Committee will offer opportunities for the scientific exchange of ideas on topics pertinent to cancer immunotherapy research and care as well as the management of cancer patients receiving immunotherapy.
Poster submissions on these topics opened on 26 June 2018 and will close on 6 September 2018 at 11pm.

All posters should be submitted via email to: Nallahverdi@hamad.qa and ANashwan@hamad.qa.
You will receive an email confirming receipt of your submission. Please contact us if you do not receive this. Decisions will be communicated by 15 September 2018.

Submissions will be reviewed and decisions communicated to the authors by 15 September 2018. The final judging of the poster submissions will take place at the workshop on 13 October 2018.
Registration will open on Saturday, 1 September 2018.

For more information about this workshop or need further clarification on the poster’s submission, please contact Ms. Niloofar Allahverdi on (Nallahverdi@hamad.qa) Or Mr. Abdulqadir Nashwan (ANashwan@hamad.qa)

Professor Alexander Knuth
CEO and Medical Director NCCCR, Chairman of Cancer Services HMC.
Chair, Qatar Cancer Research Partnership